John Oyler, CEO and Co-Founder of BeiGene, talks about BeiGene’s long-term partnership with Hillhouse and how this partnership has helped the company achieve its goals.

BeiGene is a global biotechnology company focused on delivering world-class innovative therapies at affordable prices for patients worldwide. Hillhouse invested in BeiGene in its series A and has supported the company ever since. We look forward to continuing to support them in their fight against cancer across the world.